Bausch Health Companies Inc. (BHC) 2018 Q2 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good morning. My name is Mary, and I will be your conference operator today. At this time, I would like to welcome everyone to the Bausch Health Second Quarter 2018 Earnings Call. (Operator Instructions)

    早安。我叫 Mary,今天將擔任各位的會議接線員。此刻,我想歡迎各位參加 Bausch Health 2018 年第二季財報電話會議。(接線員指示)

  • Thank you. Art Shannon, Senior Vice President of Investor Relations, you may begin your conference.

    謝謝。投資人關係資深副總裁 Art Shannon,您可以開始會議。

  • Arthur J. Shannon - Senior VP and Head of IR & Communications

    Arthur J. Shannon - Senior VP and Head of IR & Communications

  • Thank you, Mary. Good morning, everyone, and welcome to our Second Quarter 2018 Financial Results Conference Call. Participating on today's call are Chairman and Chief Executive Officer, Mr. Joe Papa; and Chief Financial Officer, Mr. Paul Herendeen. In addition to this live webcast, a copy of today's live presentation and a replay of this conference call will be available on our website under the Investor Relations section.

    謝謝你,Mary。各位早安,歡迎參加我們 2018 年第二季財務結果電話會議。今天參與會議的有董事長兼執行長 Joe Papa 先生,以及財務長 Paul Herendeen 先生。除本次即時網路直播外,今日即時簡報的副本以及本次電話會議的重播,將可於我們網站「投資人關係」專區取得。

  • Before we begin, we'd like to remind you that our presentation today contains forward-looking information. We would ask that you take a moment to read the forward-looking statement legend at the beginning of our presentation as it contains important information.

    在開始之前,我們想提醒各位,今天的簡報包含前瞻性資訊。請各位撥冗閱讀簡報開頭的前瞻性聲明說明,因其中包含重要資訊。

  • This presentation contains non-GAAP financial measures. For more information about these measures, please refer to Slide 2 of the presentation. Non-GAAP reconciliations can be found in the appendix of the presentation posted on our website.

    本簡報包含非 GAAP 財務衡量指標。關於這些衡量指標的更多資訊,請參閱簡報第 2 頁。非 GAAP 調節表可於我們網站所發布簡報的附錄中查閱。

  • Finally, the financial guidance in this presentation is effective as of today only. It is our policy to generally not update guidance until the following quarter and to not update or affirm guidance other than through broadly disseminated public disclosure.

    最後,本簡報中的財務指引僅以今日為準。我們的政策通常是在下一季之前不更新指引,且除透過廣泛散布的公開揭露外,不更新或確認指引。

  • With that, it's my pleasure to turn the call over to Joe.

    接下來,我很高興把電話交給 Joe。

  • Joseph C. Papa - CEO & Chairman of the Board

    Joseph C. Papa - CEO & Chairman of the Board

  • Thank you, Art. I'm delighted to join you this morning on our very first earnings call since we began operating under the Bausch Health name. This change was very meaning for us as the Bausch legacy defines who we are today as a company and sets the stage for our continued transformation.

    謝謝你,Art。很高興今天早上與各位一同參加我們在以 Bausch Health 名稱開始營運後的第一場財報電話會議。這項變更對我們意義重大,因為 Bausch 的傳承界定了我們今日作為一家公司的樣貌,並為我們持續轉型奠定基礎。

  • With that, let me review the topics for today's call. First, I'll cover the second quarter highlights in the core business. I'll then turn the call over to our CFO, Paul Herendeen, to review the financial results in detail and to update our 2018 guidance. Finally, we'll wrap up with a review of the segment highlights and the 2018 catalyst, including our plans for DUOBRII before opening the lines for questions.

    接著,讓我說明今天電話會議的議程。首先,我將說明核心業務在第二季的重點。接著我會把電話交給財務長 Paul Herendeen,詳細檢視財務結果並更新我們 2018 年的指引。最後,我們將回顧各事業部門的亮點與 2018 年的催化因素,包括我們對 DUOBRII 的計畫,之後再開放提問。

  • Beginning on Slide 4. As I noted in the first quarter call, our goal for 2018 is to be a year of operational excellence as we focus on revenue enhancement and optimizing our cost structure. Our second quarter results demonstrate that we remain on track to meet this goal. We delivered a great quarter of continued progress thanks to the dedication and focus of all of our employees around the world.

    從第 4 頁開始。如我在第一季電話會議中提到的,我們 2018 年的目標是成為營運卓越的一年,聚焦於提升營收並最佳化成本結構。我們第二季的結果顯示,我們仍按計畫朝此目標前進。在全球所有員工的投入與專注下,我們交出了一個持續進展、表現出色的季度。

  • Moving on to Slide 5. We continue to execute on our core businesses, delivering a second consecutive quarter of overall organic revenue growth. In addition, our top 10 products in the aggregate grew by 12% organically compared to the prior year quarter. We believe this strong sustained performance demonstrates the early steps or beginning of our transformation. On the top right, our new product pipeline is also driving growth. I want to call out the success of the LUMIFY launch, in particular. As of July 29, LUMIFY achieved a 21% market share in the Redness Reliever category, that's an incredible response to a great new product. Also, during the second quarter, Salix and US WorldMeds announced that they will be exclusively co-promoting LUCEMYRA, a nonopioid medication for opiate withdrawal symptoms, which was launched just yesterday.

    接著看第 5 頁。我們持續推進核心業務,連續第二季實現整體有機營收成長。此外,我們前 10 大產品合計的有機成長率較去年同期成長 12%。我們相信,這樣強勁且持續的表現,展現了我們轉型的早期步伐或開端。在右上角,我們的新產品研發管線也在帶動成長。我特別想強調 LUMIFY 上市的成功。截至 7 月 29 日,LUMIFY 在「消除眼紅」品類中取得 21% 的市占率,這是市場對一款優秀新產品的驚人回應。另外,在第二季期間,Salix 與 US WorldMeds 宣布將獨家共同推廣 LUCEMYRA,這是一款用於緩解鴉片類藥物戒斷症狀的非鴉片類藥物,並於昨天正式上市。

  • Moving to the bottom left, debt reduction remains a focus as well. Since the first quarter of 2016, we have reduced the company's debt by approximately $7 billion. Finally, on the legal front, we have resolved approximately 40 cases since January 1, 2018. We continue to achieve positive resolutions in the Shower-to-Shower cases with 24 complete dismissals since January 2017 and 3 pending dismissals. Johnson & Johnson continues to reimburse our legal fees and costs in these cases. Furthermore, the Philidor, Tanner and Davenport trial has been resolved with a verdict of guilty on all counts for both defendants of defrauding Valeant. We are assessing our options to seek restitution.

    再看左下角,降低負債仍是我們的重點。自 2016 年第一季以來,我們已將公司債務減少約 70 億美元。最後,在法律方面,自 2018 年 1 月 1 日以來,我們已解決約 40 件案件。我們在 Shower-to-Shower 案件中持續取得正面結果,自 2017 年 1 月以來已有 24 件完全撤訴,另有 3 件撤訴仍在待決中。Johnson & Johnson 持續在這些案件中補償我們的法律費用與成本。此外,Philidor、Tanner 與 Davenport 的審判已結案,陪審團裁定兩名被告在所有指控上均有罪,因其詐欺 Valeant。我們正在評估尋求返還賠償的選項。

  • On Slide 6. We present a snapshot of the key quarter 2 financial highlights for our 4 segments. As a reminder, we are now reporting our results in 4 segments. They are Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. This additional transparency provide an enhanced view of how each of our businesses is performing. You can refer to Slide 27 in the appendix for a detailed breakdown of which business lines are in each segment. Historical financial data recasted for the new segments will be publicly filed later this week.

    在第 6 頁,我們呈現四個事業部門第二季關鍵財務亮點的概覽。提醒各位,我們現在以四個部門揭露業績。分別為 Bausch + Lomb/International、Salix、Ortho Dermatologics 以及 Diversified Products。這項額外的透明度可更清楚地呈現各項業務的表現。各位可參閱附錄第 27 頁,以取得各部門所包含業務線的詳細拆分。依新部門重編的歷史財務資料將於本週稍晚公開申報。

  • Now onto the highlights of the quarter. 78% of our total quarter 2 revenue was generated by the Bausch + Lomb/International segment and the Salix segment, up 76% last quarter. On a combined basis, these businesses grew organically by 6% during the quarter compared to Q2 '17. Breaking it down, Salix delivered 14% organic revenue growth compared to quarter 2, 2017 and Bausch + Lomb/International grew organically by 4%.

    接著是本季亮點。我們第二季總營收的 78% 來自 Bausch + Lomb/International 部門與 Salix 部門,高於上一季的 76%。合併計算,這些業務在本季相較 2017 年第二季有機成長 6%。拆開來看,Salix 相較 2017 年第二季有機營收成長 14%,而 Bausch + Lomb/International 有機成長 4%。

  • With that, I'll turn the call over to Paul to take you through the financial results in further detail.

    接下來,我把電話交給 Paul,請他更詳細地帶各位檢視財務結果。

  • Paul S. Herendeen - Executive VP & CFO

    Paul S. Herendeen - Executive VP & CFO

  • Thank you, Joe. I'll like try to add some color to our results for the quarter.

    謝謝你,Joe。我想嘗試為本季的業績補充一些說明。

  • Start by looking at Slide 7, as I could do a quick walk down the total company P&L. Starting with revenue. Compared with Q2 of '17, revenue was down 5% on a reported basis, down 6% on a constant-currency basis as FX was a bit of a helper versus the prior year, but up 3% organically. As Joe said, this is the second consecutive quarter where we posted organic growth, a good thing for sure. A quick reminder. When we talk about organic growth that means on a constant-currency basis and adjusted for divestitures. The Salix segment was a top driver of organic growth, both in terms of percentage increase, 14% and in dollar contribution to organic growth, followed by the B + L/International segment at plus 4% organic growth. Our Diversified segment was a major organic growth drag, down 8%, while Ortho Dermatologics was down 11%.

    先看第 7 頁,我可以快速帶各位走一遍公司整體損益表。先從營收開始。與 2017 年第二季相比,營收以報告基礎計算下降 5%,以固定匯率基礎計算下降 6%,因為匯率相較去年對我們略有助益,但以有機口徑計算則成長 3%。如 Joe 所說,這是我們連續第二季呈現有機成長,確實是件好事。快速提醒一下。當我們談到有機成長,指的是以固定匯率基礎並剔除資產處分影響後的成長。Salix 部門是有機成長的主要驅動因素,無論是成長百分比(14%)或對有機成長的金額貢獻,其次是 B + L/International 部門,有機成長 4%。我們的 Diversified 部門對有機成長造成主要拖累,下滑 8%,而 Ortho Dermatologics 下滑 11%。

  • Our basket of LOE assets shown on Slides 28 and 29 continue to dampen our organic growth, declining some $70 million compared with Q2 of 2017, mainly in the Diversified segment. Excluding the growth drag from the LOE assets, our organic growth would have been more like plus 6%, pretty good, right. Important safety tip though. If you look at Slide 28, you'll see that we expect the revenue growth drag from the LOE assets to be $358 million for the full year 2018 versus 2017, with a greater impact in the second half of the year. Year-to-date, the LOE assets accounted for a revenue decline of $125 million compared with the first half of '17, meaning we're currently expecting to see a decline in that basket of products of roughly [$233 million] over the back half of 2018. So you need to bear that in mind as you think about how the balance of 2018 will play out, particularly the impact of the LOE assets on our second half growth rate.

    我們在投影片28與29所示的LOE資產組合,持續抑制我們的有機成長;相較於2017年第二季,營收下滑約7,000萬美元,主要發生在多元化(Diversified)事業部門。若排除LOE資產對成長的拖累,我們的有機成長率會更接近正6%,相當不錯,對吧。不過有個重要的安全提醒。如果你看投影片28,你會看到我們預期LOE資產對營收成長的拖累,在2018全年相較2017年將達3.58億美元,且影響在下半年更大。年初至今,LOE資產相較於2017年上半年造成營收下滑1.25億美元,這表示我們目前預期在2018年下半年,該產品組合將約下滑[2.33億美元]。因此,當你思考2018年剩餘期間的走勢時,特別是LOE資產對我們下半年成長率的影響,務必將此納入考量。

  • Next, our gross margin improved by some 100 basis points compared with last year, mainly due to improved mix in the Salix and Diversified portfolios. Gross margin in the Salix segment improved by roughly 330 basis points due to mix as we posted lower sales of Glumetza, which carries a lower gross margin relative to other Salix products. In Diversified, gross margins improved. In neuro, due to mix, mainly lesser sales of Xenazine authorized generic in the U.S. generics business due to mix with lesser sales of our Glumetza authorized generic and overall due to the divestiture of Dendreon, which is in the prior year quarter.

    接著,我們的毛利率較去年提升約100個基點,主要來自Salix與多元化(Diversified)產品組合的組合改善。Salix事業部門的毛利率因產品組合因素提升約330個基點,因為我們的Glumetza銷售較低;相較其他Salix產品,Glumetza的毛利率較低。在多元化(Diversified)方面,毛利率也有所改善。在神經科(neuro)方面,因產品組合因素,主要是美國學名藥業務中Xenazine授權學名藥銷售較少;同時也因我們的Glumetza授權學名藥銷售較少,以及整體上因前一年同季包含Dendreon的剝離(divestiture)影響。

  • Margins in the B + L/International segment declined by roughly 45 basis points, driven by lower margins in the U.S. Vision Care due to product mix and greater user price discounts to drive unit share increases and lower margins in our Amoun unit due to the lingering effects from the devaluation of the Egyptian pound. On the plus side, gross margins in B + L/International -- our gross margins improved in Europe, Latin America and in our international surgical business.

    B + L/International事業部門的利潤率下滑約45個基點,主因是美國視力保健(U.S. Vision Care)因產品組合導致利潤率較低,且為提升單位市占而提供更高的用戶價格折扣;另外,我們的Amoun單位利潤率較低,係因埃及鎊貶值的影響仍在延續。正面來看,B + L/International的毛利率——我們在歐洲、拉丁美洲以及國際手術業務的毛利率有所改善。

  • On a constant-currency basis, our company-wide operating expenses were favorable compared with Q2 of '17. However, adjusted for the divested assets, meaning on organic basis, we actually increased overspending, particularly in selling, advertising and promotional expenses as we continue to play the longer game and invest behind our growth opportunities. I'll provide a few specifics as we go through the individual segments. On an organic basis, our adjusted EBITDA grew 3% compared with the prior year quarter. All in all, a very strong solid quarter.

    以固定匯率(constant-currency)計算,我們全公司的營業費用相較2017年第二季表現有利。然而,若就已剝離資產進行調整、也就是以有機基礎(organic basis)來看,我們實際上增加了超支,特別是在銷售、廣告與促銷費用方面,因為我們持續採取較長期的策略,並加大對成長機會的投資。在我們逐一檢視各事業部門時,我會提供一些具體細節。以有機基礎計算,我們的調整後EBITDA較去年同季成長3%。總體而言,這是一個非常強勁且穩健的季度。

  • Let's turn to our segments, now as Joe said, numbering 4. Starting with B + L/International on Slide 8. The headline here is that the segment revenue was up 4% organically versus Q2 of '17. Some important color. The 4% organic growth in the segment was driven by 5% increase in volume, offset in part by 1% decrease in realized net prices. So in my opinion, the best kind of fundamental growth. All 5 B + L business units showed organic growth over the prior quarter. Global Vision Care up 9%; Consumer up 5%; Global Ophtho Rx up 5%, Global Surgical up 2% and international pharma up 1%. This is the second consecutive quarter that the Global Vision Care business grew 9% organically in both U.S. Vision Care under Joe Gordon's leadership and International Vision Care under Tom Appio have now delivered 4 quarters of solid growth compared with the prior years' quarters.

    現在來看各事業部門,如Joe所說,共4個。先從投影片8的B + L/International開始。重點是:該部門營收相較2017年第二季有機成長4%。補充一些重要背景。該部門4%的有機成長由銷量增加5%所帶動,但部分被已實現淨價格下降1%所抵銷。所以在我看來,這是最理想的基本面成長。所有5個B + L業務單位相較前一季皆呈現有機成長。全球視力保健成長9%;消費者業務成長5%;全球眼科處方藥(Global Ophtho Rx)成長5%;全球手術成長2%;國際製藥成長1%。這是全球視力保健業務連續第二個季度有機成長9%;在Joe Gordon領導下的美國視力保健,以及在Tom Appio領導下的國際視力保健,現在都已連續4個季度相較前一年同期交出穩健成長。

  • Global Consumer also grew both in the U.S. and international parts of the business, with the U.S. a bit stronger helped along by the launch of LUMIFY. The organic growth in Global Ophtho Rx came from outside the U.S. with strong results across most regions, including in Europe, particularly the U.K. and the Asia PAC region. Our Global Surgical business continues to be stronger outside the U.S. As we improve in the U.S., we believe the Global Surgical business has the prospect to improve on the low single-digit organic growth we've seen over the last 4 quarters.

    全球消費者業務在美國與國際市場也都成長,其中美國表現略強,部分受惠於LUMIFY的上市。全球眼科處方藥(Global Ophtho Rx)的有機成長來自美國以外市場,多數地區表現強勁,包括歐洲(尤其英國)以及亞太地區。我們的全球手術業務在美國以外市場持續更強。隨著我們在美國市場改善,我們相信全球手術業務有機會優於過去4個季度所見的低個位數有機成長。

  • International Pharma has been an area of focus for us, and to be frank, we have not yet been able to deliver the consistency in performance across all geographies that we are looking for. We delivered 1% organic growth in the quarter with strength in Latin America and modest growth across a number of other markets, and that was blunted by the impact by LOEs in Canada and weakness in some Eastern European markets, and that's mainly Romania and Serbia. We recently have taken positive steps towards reorganizing international pharma, and we're excited about the longer-range prospects for this business.

    國際製藥一直是我們的重點領域;坦白說,我們尚未能在所有地理區域交出我們所期待的一致性表現。本季度我們達成1%的有機成長,拉丁美洲表現強勁,其他多個市場也有溫和成長;但加拿大的LOE影響以及部分東歐市場疲弱——主要是羅馬尼亞與塞爾維亞——削弱了成長。我們近期已採取正向措施,推動國際製藥的重整,我們也對這項業務的長期前景感到振奮。

  • Within operating expenses in B + L/International, it looks like selling, advertising and promotional expenses were up or unfavorable on a constant-currency basis by 2%. But further adjusted for the divestitures, those -- the expenses were up more than that, but for good reasons. We're investing more to drive growth as we allocate capital to support the launches of new products in the segment like LUMIFY, for DTC advertising that continue to drive sales growth of other U.S. consumer products like our eye vitamins, and in the U.S. Vision Care business to fund more fit sets to continue the string of strong growth we've delivered over the last 4 quarters. Overall, another solid quarter from this segment.

    在B + L/International的營業費用中,以固定匯率計算,銷售、廣告與促銷費用增加或呈不利約2%。但若再就剝離事項進一步調整,這些——費用增幅其實更高,但原因正當。我們加大投資以推動成長,透過資本配置來支持該部門新產品(如LUMIFY)的上市;投入DTC(直接面向消費者)廣告以持續帶動其他美國消費者產品(如我們的眼部維他命)的銷售成長;並在美國視力保健業務中投入更多試戴組(fit sets),以延續我們過去4個季度所交出的強勁成長。整體而言,該部門又是一個穩健的季度。

  • On to Salix on Slide 9. Mark McKenna and the Salix team continued to deliver solid fundamental performance based on excellence in execution. XIFAXAN achieved record revenue of $294 million in the quarter, up 26% over Q2 of 2017, with that growth balanced between improved net pricing and volume gains. Recall that in Q1, we talked about over successful efforts to address and improve XIFAXAN pricing in nonretail channels. Those changes continued to benefit us in Q2 relative to the prior year and are expected to continue to be a growth tailwind for us through Q4 of this year.

    接著看投影片9的Salix。Mark McKenna與Salix團隊持續以卓越的執行力,交出穩健的基本面表現。XIFAXAN本季度營收達2.94億美元創新高,較2017年第二季成長26%,成長動能在淨價格改善與銷量提升之間取得平衡。回顧第一季,我們談到在非零售通路成功推動改善XIFAXAN定價的措施。這些變更在第二季相較去年同期持續帶來效益,並預期將持續成為我們今年至第四季的成長順風。

  • XIFAXAN retail Rxs were up 8% year-over-year and up 6% sequentially. The RELISTOR franchise grew 43% versus Q2 of '17, aided by 32% increase in filled prescriptions. APRISO and UCERIS showed growth in Q2 of '17 -- versus Q2 of '17 as well. The performance of the promoted assets in the portfolio overwhelmed the impact of LOEs for Glumetza and Zegerid, a really good quarter, all the more impressive when you consider that selling, advertising and promotional expenses were 10% favorable to the prior quarter, great stuff.

    XIFAXAN零售處方量(retail Rxs)年增8%,且較前一季成長6%。RELISTOR系列產品較2017年第二季成長43%,其中已配藥處方(filled prescriptions)增加32%提供助力。APRISO與UCERIS在第二季相較2017年第二季也呈現成長。產品組合中受推廣資產的表現,完全抵銷了Glumetza與Zegerid的LOE影響;這是一個非常好的季度,更令人印象深刻的是,銷售、廣告與促銷費用較前一季有利10%,表現非常出色。

  • On to Slide 10, the Ortho Dermatologic segment, which includes our U.S. medical dermatology business and our global Solta aesthetics equipment unit. The dermatology business continues to face challenges based on the aggressiveness of third-party payers in limiting or blocking reimbursement of products like those that comprise much of our legacy product portfolio. Despite that environment, Bill Humphries and his sales and marketing team are continuing to drive Rxs even for our more challenged brands. For certain of our derm products where the market dynamics are a bit more favorable, we're generating real growth in prescriptions and in net sales, for example, with the Retin-A Micro franchise, with Elidel, with ONEXTON and with SILIQ. SILIQ is a slow build but week to week to week, we are seeing more physicians write the product, our script count grow, and we recorded net sales of $4 million in the quarter. We are committed to making SILIQ a success, particularly as I referenced with SILIQ, set the stage for the innovative products, BRYHALI and DUOBRII, expected to be launched later this year and in 2019.

    接著看第10頁投影片:Ortho Dermatologic(皮膚科)事業部,涵蓋我們在美國的醫療皮膚科業務,以及全球的 Solta 醫美設備事業單位。皮膚科業務持續面臨挑戰,原因在於第三方支付方在限制或阻擋報銷方面的強硬作法,尤其針對像我們多數傳統產品組合所涵蓋的產品。儘管處於這樣的環境,Bill Humphries 及其銷售與行銷團隊仍持續推動處方量(Rxs),即使是對我們較具挑戰的品牌亦然。對於部分市場動態較為有利的皮膚科產品,我們在處方量與淨銷售額方面正實現實質成長,例如 Retin-A Micro 系列、Elidel、ONEXTON 以及 SILIQ。SILIQ 的成長屬於緩步建立,但一週接著一週,我們看到更多醫師開立該產品、處方數持續增加,且本季錄得 400 萬美元的淨銷售額。我們致力於讓 SILIQ 成功,尤其如我提到的,SILIQ 也為創新產品 BRYHALI 與 DUOBRII 奠定基礎,預計將於今年稍晚及 2019 年上市。

  • The other business in this segment, our aesthetics company Solta, was an undermanaged, underperforming unit that has responded well to the introduction of a new management team led by Tom Hart. Global Solta grew 14% versus the prior quarter. Overall, we're looking for the Ortho Dermatologics segment to find its space and return to a growth mode as we shift the dermatology portfolio to one based on innovative, differentiated products that will in -- excuse me, will provide important patient benefits, be embraced by physicians and importantly, be valued by payers.

    本事業部的另一項業務——我們的醫美公司 Solta——過去管理不足、表現不佳;在 Tom Hart 領導的新管理團隊上任後,已對此產生良好回應。全球 Solta 較上一季成長 14%。整體而言,隨著我們將皮膚科產品組合轉向以創新、差異化產品為核心——呃,抱歉——這些產品將帶來重要的病患效益、獲得醫師採用,且更重要的是,能被支付方認可其價值——我們期待 Ortho Dermatologics 事業部找到其定位並回到成長模式。

  • On to the Diversified segment, which is shown on Slide 11. Note that under our new segment structure, this is where you will find the 2017 results for many of our divested businesses, including Dendreon, Obagi and Women's Health. This is also where you see the majority of the impact of the LOEs, mainly in Neuro, where the LOE assets accounted for $57 million decline. So setting aside the unstoppable decline of the LOE assets and the impact of the divested businesses, the Diversified segment actually grew compared to Q2 of '17 on strength in our Neuro and U.S. generics businesses.

    接著看多元化(Diversified)事業部,如第11頁投影片所示。請注意,在我們新的事業部分類架構下,這裡會包含我們多項已出售業務在 2017 年的結果,包括 Dendreon、Obagi 與 Women's Health(女性健康)。這裡也呈現了專利到期(LOE)的主要影響,主要在神經科(Neuro),其中 LOE 資產造成 5,700 萬美元的下滑。因此,若先排除 LOE 資產不可避免的下滑以及已出售業務的影響,多元化事業部相較 2017 年第二季其實是成長的,主要受惠於我們的神經科與美國學名藥業務的強勁表現。

  • On to Slide 12 and over the balance sheet summary. Not a lot of change from the end of Q1. Just note that we did draw down a net amount of $75 million of our revolver in the quarter as we had a concatenation of funding requirements, including for closing costs for the June financing transaction and some associated accelerated interest payments. Just yesterday, we repaid $132 million of debt, including $75 million of our revolver. We will continue to prioritize the use of available cash to prepay debt.

    接著看第12頁,進入資產負債表摘要。相較第一季末沒有太多變化。僅需注意的是,本季我們的循環信貸(revolver)淨動用 7,500 萬美元,因為我們同時面臨一連串資金需求,包括 6 月融資交易的結案成本,以及部分相關的加速利息支付。就在昨天,我們已償還 1.32 億美元的債務,其中包括循環信貸的 7,500 萬美元。我們將持續優先運用可用現金來提前償還債務。

  • Turning to Slide 13, a familiar slide, showing our continued progress on addressing future maturities of our debt. We have a very manageable amount of debts coming -- excuse me debt coming due in -- out to 2021. If you look at the March 31, 2016 line in the graph and the degree to which we've reduced the quantum of our debt and expanded our maturity profile, it shows that we've given ourselves the runway to continue the transformation of the company. We've also been able to modify our covenants such that we substantially reduced over covenant risk, enhanced our access to capital and gained flexibility to manage our financial affairs. Here is a remarkable factoid for you. Since March of 2017, a short 16 months ago, we've completed 6 refinancing transactions, raising a total of more than $16 billion in term loans, unsecured bonds and secured bonds. To all of our debt investors out there, we could not have done that without you, so thank you for your support.

    接著看第13頁,這是一張熟悉的投影片,顯示我們在處理未來到期債務方面的持續進展。我們在——呃,抱歉——到 2021 年之前到期的債務金額相當可控。若你看圖表中 2016 年 3 月 31 日那條線,以及我們降低債務規模並延長到期結構的幅度,這顯示我們已為公司持續轉型爭取到足夠的時間與空間。我們也已能調整財務契約(covenants),使我們大幅降低違約風險、提升資本取得能力,並獲得管理財務事務的彈性。這裡有個值得一提的小數據。自 2017 年 3 月以來,也就是短短 16 個月前,我們已完成 6 筆再融資交易,合計募集超過 160 億美元,涵蓋定期貸款、無擔保債券與有擔保債券。對所有債務投資人而言,沒有你們我們做不到,因此感謝你們的支持。

  • On Slide 14, you see our cash flow summary for the quarter. First, I want to point out that our second quarter is generally a softer quarter for generation of cash from operating activities. We generated $222 million from ops, with that amount depressed by the settlement of legacy legal liabilities for roughly $50 million and the acceleration of $57 million of interest payments in connection with the June refinancing transaction. Divested assets -- compared to prior year, divested assets reduced our operating cash flow by $70 million. Working capital days decreased by some 25%, or 70 days, when compared to back to March 31 of 2016, which freed up approximately $1 billion of cash, which we used to retire debt, good stuff.

    在第14頁,你會看到我們本季的現金流摘要。首先,我想指出第二季通常是營運活動現金產生較弱的一季。我們的營運現金流入為 2.22 億美元;該金額受到兩項因素壓抑:就歷史法律責任的和解支付約 5,000 萬美元,以及因 6 月再融資交易而加速支付 5,700 萬美元利息。已出售資產——相較去年——使我們的營運現金流減少 7,000 萬美元。與 2016 年 3 月 31 日相比,我們的營運資金週轉天數下降約 25%,也就是 70 天,釋放約 10 億美元現金,我們用來償還債務,這很不錯。

  • Finally, from me, on Slides 15 and 16, you see our revised guidance for the full year 2018. We're holding our revenue guidance in the range of $8.15 billion to $8.35 billion despite a roughly $60 million FX headwind, and we're raising our adjusted EBITDA guidance by $50 million across the range to $3.20 billion to $3.35 billion, reflecting an improved outlook for other businesses.

    最後,就我這邊,在第15與第16頁,你會看到我們對 2018 全年最新的財測指引。儘管面臨約 6,000 萬美元的匯率(FX)逆風,我們仍維持營收指引在 81.5 億至 83.5 億美元區間;同時,我們將調整後 EBITDA 指引在全區間上調 5,000 萬美元至 32.0 億至 33.5 億美元,反映其他業務展望改善。

  • We've also updated several of our full year assumptions, so I call your attention to those on Slide 15. Note that we've reduced our expectations for CapEx for the year by $50 million due to timing. Our growth CapEx initiatives to support our daily silicone hydrogel lens project is proceeding, but the phasing of that spend has been pushed out a bit.

    我們也更新了數項全年假設,請特別留意第15頁所列內容。請注意,由於時程因素,我們將今年資本支出(CapEx)的預期下調 5,000 萬美元。我們為支持日拋矽水膠隱形眼鏡專案所推動的成長型資本支出計畫仍在進行中,但支出節奏被稍微往後延。

  • With that, let me turn it back to Joe.

    接下來,我把時間交回給 Joe。

  • Joseph C. Papa - CEO & Chairman of the Board

    Joseph C. Papa - CEO & Chairman of the Board

  • Thank you, Paul. We have a lot to talk about the B + L/International segment on Slide 17. First, this segment generated 57% of total company revenue with organic growth of 4% driven by volume as well as growth in Europe and China. Importantly, as Paul mentioned, every business line in this segment grew organically during the second quarter, which speaks to the overall strength of this business.

    謝謝你,Paul。我們在第17頁投影片的 B + L/國際事業部有很多內容要談。首先,該事業部貢獻公司總營收的 57%,有機成長 4%,主要由銷量帶動,並受惠於歐洲與中國的成長。重要的是,如 Paul 所提到,本事業部在第二季的每一條業務線都實現有機成長,這反映出整體業務的強勁實力。

  • In the U.S., we had a number of highlights in the consumer business. In addition to LUMIFY, we launched 3 additional products, Soothe XP Preservative Free lubricant eye drops, Ocuvite Blue Light eye vitamin and PreserVision AREDS 2 Formula chewable vitamins. The e-commerce also remains a strong trend for our consumer products. Sales through Amazon showed continued strength, up 48% in the second quarter of 2018 versus a year ago. Global Vision Care was up 9% organically compared to the prior year quarter. In the U.S., sales growth was driven by continued market share gains, launch of new products and strong field execution. For International, better-than-expected results were driven by the strong execution in the Asia Pacific region, Latin America and Canada.

    在美國,我們的消費者業務有多項亮點。除了 LUMIFY 之外,我們還推出另外 3 項產品:Soothe XP 無防腐劑潤滑眼藥水、Ocuvite Blue Light 藍光護眼維他命,以及 PreserVision AREDS 2 配方咀嚼錠維他命。電商也仍是我們消費者產品的強勁趨勢。透過 Amazon 的銷售持續強勁,2018 年第二季較去年同期成長 48%。全球視力保健(Vision Care)業務較去年同期有機成長 9%。在美國,銷售成長來自持續提升的市占率、新產品上市以及強勁的前線執行力。在國際市場,優於預期的結果主要由亞太地區、拉丁美洲與加拿大的強勁執行所帶動。

  • On the bottom right, we've included the weekly script data for VYZULTA since the beginning of the year. The chart, which shows a strong positive trend for TRx growth. Please note, the initial VYZULTA launch scripts represented approximately a 2-month supply, so that's something to keep in mind when you review this data. The other point I want to emphasize is that Medicare Part D makes up 60% of the glaucoma market, and we are expecting VYZULTA access in the Medicare Part D in 2019. So there are a number of positive factors that will create additional opportunities for VYZULTA in the future.

    在右下角,我們納入了 VYZULTA 自年初以來的每週處方數據。該圖表顯示 TRx(總處方量)成長呈現強勁的正向趨勢。請注意,VYZULTA 初期上市的處方量約代表 2 個月的供應量,因此在你檢視這些數據時需將此因素納入考量。我想強調的另一點是,Medicare Part D 佔青光眼市場的 60%,而我們預期 VYZULTA 將於 2019 年取得 Medicare Part D 的給付可近性。因此,未來有多項正面因素將為 VYZULTA 帶來更多額外機會。

  • Turning now to Slide 18 on Salix. We continued to see strong execution across all promoted brands. First, XIFAXAN increased by 26% versus the prior year quarter on strong volume driven largely by primary care. As the chart on the right demonstrates the new Rx share is up 20 points since February 2017 from 24% to 44% in primary care due to field execution. And we think there's a lot more opportunity for XIFAXAN in primary care.

    現在轉到關於 Salix 的第 18 張投影片。我們持續看到所有推廣品牌皆有強勁的執行表現。首先,XIFAXAN 在基層醫療帶動的強勁銷量推升下,較去年同期季度成長 26%。如右側圖表所示,由於前線執行到位,自 2017 年 2 月以來,基層醫療的新處方(new Rx)市占率上升了 20 個百分點,從 24% 提升至 44%。我們認為 XIFAXAN 在基層醫療仍有更多機會。

  • Moving now to the RELISTOR franchise. Revenue was up by 43% compared to the second quarter of 2017. And as you can see from the chart in the lower right, RELISTOR TRx were up 34% in the first 30 weeks of 2018 versus 2017.

    接著談 RELISTOR 產品線。營收較 2017 年第二季成長 43%。如右下方圖表所示,2018 年前 30 週 RELISTOR 的總處方量(TRx)較 2017 年成長 34%。

  • Finally, I want to touch on 2 new Salix products. Let's turn to Slide #19. As I mentioned earlier, we are pleased with a strong fundamental execution across all Salix promoted brands, and there is more to doing -- that we are doing to build up this business, such as acquiring the rights for our sales reps to promote additional products. Our first LUCEMYRA, the first and only nonopioid medication for the mitigation of withdrawal symptoms after abrupt discontinuation of opioids in adults. We believe there is a huge unmet need in this market for a nonopioid to mitigate withdrawal symptoms, which can include physical pain and sleep disturbances. Tragically, more than 115 people die every day after overdosing on opioid-related products. We now have a product with a potential to help those who are suffering from symptoms of opioid withdrawal, and LUCEMYRA is a perfect fit for our sales reps. We're already promoting RELISTOR for opioid-induced constipation.

    最後,我想談談 2 項新的 Salix 產品。請看第 19 張投影片。如我先前提到的,我們對 Salix 所有推廣品牌的強勁基本面執行感到滿意,而且我們也正在做更多工作來壯大這項業務,例如取得權利,讓我們的業務代表可推廣更多產品。第一項是 LUCEMYRA,這是成人在突然停止使用鴉片類藥物後,用於緩解戒斷症狀的第一且唯一非鴉片類藥物。我們相信市場對於可緩解戒斷症狀的非鴉片類藥物存在巨大的未被滿足需求;戒斷症狀可能包括身體疼痛與睡眠障礙。令人痛心的是,每天有超過 115 人因鴉片類相關產品過量而死亡。我們現在擁有一項產品,具備幫助那些正承受鴉片類戒斷症狀患者的潛力,而 LUCEMYRA 也非常適合我們的業務代表推廣。我們已在推廣 RELISTOR,用於治療鴉片類引起的便祕。

  • The second new product we are preparing to launch is PLENVU, a next-generation bowel cleansing preparation for colonoscopy. The U.S. colonoscopy market represents a significant opportunity with more than 15 million procedures performed annually. Patient complaints about bowel preparations typically related large volumes of fluid that the patient is required to consume and the unpleasant taste. PLENVU, which is designed to improve patient acceptability and compliance will be the lowest total volume bowel cleanser available in the United States. We expect PLENVU to be available in September.

    第二項我們正準備上市的新產品是 PLENVU,這是一種用於大腸鏡檢查的次世代腸道清潔製劑。美國大腸鏡市場代表著顯著的機會,每年進行超過 1,500 萬例手術。患者對腸道清潔準備的抱怨通常與需要飲用大量液體以及不佳的口感有關。PLENVU 的設計旨在提升患者接受度與依從性,將成為美國可取得的總用量最低的腸道清潔劑。我們預期 PLENVU 將於 9 月上市。

  • I also want to highlight 2 additional expansions of our GI portfolio. First, we've agreed to extend our existing collaboration with Dr. Falk by agreeing on terms to license 3 additional budesonide programs. And we also have announced a collaboration with Cedars-Sinai Medical Center and the lab of world-renowned researcher, Dr. Mark Pimentel, to further investigate the microbiome in the treatment of GI disorders. We're excited by the scientific collaborations like these because they will help us to continue to position Salix as a trusted partner to the commitment to support clinical R&D and create a new innovative treatments for patients.

    我也想強調我們 GI 產品組合的另外 2 項擴展。首先,我們已同意延長與 Dr. Falk 的既有合作,並就授權 3 項額外的布地奈德(budesonide)計畫達成條款。此外,我們也宣布與 Cedars-Sinai 醫學中心以及世界知名研究者 Mark Pimentel 醫師的實驗室合作,以進一步研究微生物組在 GI 疾病治療中的角色。我們對這類科學合作感到振奮,因為它們將協助我們持續把 Salix 定位為值得信賴的合作夥伴,致力於支持臨床研發,並為患者創造新的創新療法。

  • Moving on to Slide 20. While we saw total organic revenue decline of 11% in Q2, global Solta organic revenue growth of 14% was a bright spot for the quarter. As we continue to stabilize Ortho Dermatologics business, our focus has been on building out our pipeline and launching new products. We plan to double our dermatology franchise by 2022 and the 9 new product launches we are working, are expected to drive that growth.

    接著看第 20 張投影片。雖然我們在第二季看到總有機營收下滑 11%,但 Solta 全球有機營收成長 14% 是本季的一大亮點。在我們持續穩定 Ortho Dermatologics 業務的同時,重點一直放在擴充產品線並推出新產品。我們計畫在 2022 年前將皮膚科事業規模倍增,而我們正在推進的 9 項新產品上市預期將帶動該成長。

  • Let's talk about 2 recent launches in particular, SILIQ and Retin-A Micro 0.06%. First on SILIQ. We're pleased to see that TRx weekly scripts nearly tripled in the second quarter compared to the first quarter due to marketing initiatives and continued REMS certification. We invested time and energy to get doctors REMS certified over the last year. We have now over 3,500 REMS certified physicians, and we are starting to see the results. The other point I'd emphasize on SILIQ is the better-than-average adherence data versus the other injectable biologics. The patients who are using SILIQ are sticking with it.

    特別談談近期的 2 項上市產品:SILIQ 與 Retin-A Micro 0.06%。先談 SILIQ。我們很高興看到,由於行銷措施以及持續的 REMS 認證,第二季每週總處方量(TRx)幾乎是第一季的三倍。過去一年我們投入時間與精力協助醫師取得 REMS 認證。目前已有超過 3,500 位醫師完成 REMS 認證,我們開始看到成果。關於 SILIQ 我還要強調的一點是,相較其他可注射生物製劑,其依從性數據優於平均。使用 SILIQ 的患者持續用藥的比例更高。

  • With respect to Retin-A Micro franchise, we provided TRx data for 2018 versus 2017 in the graph in the lower-right corner. On a combined basis, the 0.06% and 0.08% products saw a greater than 50% TRx growth in the second quarter 2018 versus last year, and we're pleased to see this continued strength. These results are a great example of the capabilities of our derm sales force. Despite operating in very challenging reimbursement environment for some of our legacy products, the Ortho Dermatologics sales force are doing a great job of driving prescriptions for Retin-A which speaks to our ability to commercialize our new product pipeline.

    至於 Retin-A Micro 產品線,我們在右下角圖表提供了 2018 年相較 2017 年的總處方量(TRx)數據。合併來看,0.06% 與 0.08% 產品在 2018 年第二季的 TRx 較去年成長超過 50%,我們很高興看到這股強勢延續。這些結果充分展現我們皮膚科業務團隊的能力。儘管我們部分既有產品面臨非常具挑戰性的給付環境,Ortho Dermatologics 的業務團隊仍在推動 Retin-A 處方方面表現出色,這也證明我們具備將新產品線商業化的能力。

  • Let me now take a moment to address the recent DUOBRII development on Slide 21. As we announced in mid-June, we received a CRL, or a Complete Response Letter, from the FDA. Importantly, the CRL did not specify any deficiencies related to the clinical efficacy or safety of DUOBRII and have identified no issues with the CMC processes. The CRL only noted questions regarding pharmacokinetic data relates to the time course of drug absorption, distribution, metabolism and excretion and leads to things like the maximum concentration. We are working to resolve this matter expeditiously and have already met with the FDA. We understand the additional data requirements and expect to resubmit with additional data to the FDA within 30 days, if not sooner. We expect that this will be a Class II filing, which has a 6-month review cycle. We continue to have confidence in the -- in an approval and hope to bring forward this important new treatment option for those with psoriasis as quickly as possible.

    接下來我想花點時間說明第 21 張投影片中 DUOBRII 的最新進展。如我們在 6 月中旬宣布的,我們收到 FDA 的 CRL(Complete Response Letter,完整回覆函)。重要的是,CRL 並未指出任何與 DUOBRII 臨床療效或安全性相關的缺失,也未發現 CMC(化學、製造與管制)流程的問題。CRL 僅提出與藥物動力學數據相關的疑問,涉及藥物吸收、分布、代謝與排泄的時間進程,並影響例如最高濃度等指標。我們正加速處理此事,且已與 FDA 會面。我們已了解額外數據的要求,並預期在 30 天內(甚至更快)向 FDA 重新提交補充資料。我們預期這將屬於第二類(Class II)申請,審查週期為 6 個月。我們仍對獲准充滿信心,並希望盡快為乾癬患者帶來這項重要的新治療選擇。

  • Staying on Ortho Dermatologics, let's move to Slide #22 and talk about BRYHALI, the first high-potency topical steroid for psoriasis with expected dosing up to 8 weeks. The results of the Phase III study are clearly demonstrating looking at each of the signs and symptoms that define psoriasis in the graph on the right, erythema, plaque elevation and scaling at 4 weeks post treatment. Importantly, BRYHALI provides a clinical effective therapy using a formulation that is 1/5 the strength of other halobetasol products. We're pleased with these results and look forward to giving patients another topical option to treat psoriasis.

    延續 Ortho Dermatologics,請看第 22 張投影片,談談 BRYHALI:這是第一款用於乾癬的高效力外用類固醇,預期給藥可長達 8 週。第三期研究結果清楚顯示,如右側圖表所示,在治療後第 4 週,針對定義乾癬的各項徵象與症狀——紅斑、斑塊隆起與脫屑——皆有改善。重要的是,BRYHALI 以僅為其他 halobetasol 產品 1/5 濃度的配方,即可提供臨床上有效的治療。我們對這些結果感到滿意,並期待為患者提供另一種治療乾癬的外用選擇。

  • Acne continues to be an area for focus for us as well. As the most common disease in the United States, we estimate as many as 50 million people have this skin condition. On the bottom left ALTRENO, if approved, will be the first tretinoin product that will be available in a lotion form rather than a gel and cream. And importantly, it's aesthetically pleasing and deliveries efficacy with an acceptable irritation profile that will be suitable for the face. Phase III results demonstrated statistically significant improvement in achieving clear to almost clear scores and a statistically significant reduction in inflammatory and non-inflammatory facial lesions.

    痤瘡(青春痘)也仍是我們的重點領域。作為美國最常見的疾病,我們估計多達 5,000 萬人有此皮膚狀況。在左下方,ALTRENO 若獲核准,將成為第一款以乳液劑型(而非凝膠或乳霜)提供的 tretinoin 產品。而且重要的是,它在外觀與使用感受上更佳,同時能提供療效並具可接受的刺激性特徵,適用於臉部。第三期結果顯示,在達到「清除至幾乎清除」評分方面有統計上顯著的改善,且臉部發炎性與非發炎性病灶均有統計上顯著的降低。

  • Our late-stage pipeline for acne and atopic dermatitis is strong and shows a lot of promise with 2 ongoing Phase III studies for innovative new treatments and a third expected to begin in the second half of 2018. We also have ongoing Phase II studies for a triple combination topical acne treatment.

    我們在痤瘡與異位性皮膚炎方面的後期研發管線相當強勁,前景可期;目前有 2 項創新新療法正在進行第三期臨床試驗,另有第 3 項預計將於 2018 年下半年啟動。我們也正在進行一項三合一複方外用痤瘡治療的第二期臨床試驗。

  • Moving on to Slide #23. Here we have the Significant Seven, which represent the expected core growth drivers in our business over the next 5 years. As you can see on the time line, 4 of the 7 products have launched. The next anticipated launch will be the BRYHALI PDUFA date in October 5, followed by an expected SiHy Daily launch in the fourth quarter. And we'll, of course, keep you priced of the revised time line for DUOBRII as we resubmit to the FDA.

    接著看第 23 張投影片。這裡是「重要七項」(Significant Seven),代表未來 5 年我們業務預期的核心成長驅動因素。如時間軸所示,7 項產品中已有 4 項上市。下一個預期上市的是 BRYHALI,PDUFA 日期為 10 月 5 日,之後預計第四季推出 SiHy Daily。當我們向 FDA 重新遞交 DUOBRII 申請時,當然也會持續向各位更新修訂後的時間表。

  • On Slide 24, we put together a chart with more detail on our later-phase pipeline. As you can see, each of these 3 segments is actively developing and launching new products that we believe will expand our portfolio and fuel our future growth. We plan to continue to grow our investments in research and development.

    在第 24 張投影片,我們整理了一張圖表,更詳細說明我們後期研發管線。如各位所見,這 3 個區塊都在積極開發並推出新產品,我們相信這將擴大產品組合並推動未來成長。我們計畫持續增加對研發的投資。

  • And finally, on Slide 25, reviews the 2018 commitments and expected targets we outlined at the beginning of the year. Having delivered 2 consecutive quarters of overall organic revenue growth, along with the continued debt repayment and a robust late-stage pipeline, Bausch Health is well positioned to deliver on these commitments and our targets. Anticipating questions may be on the mind of many of you with respect to pricing, we are not going to take any price increases on our U.S. branded prescription drugs for the remainder of the year. One unique advantage for Bausch Health is that approximately 54% of our revenues come from a diversified mix of medical devices, over-the-counter products, prescription and branded generic products sold outside of the United States. In other words, 54% of our products are not exposed to U.S. branded prescription drug pricing environment.

    最後,第 25 張投影片回顧我們在年初所提出的 2018 年承諾與預期目標。在連續兩季實現整體有機營收成長、持續償還債務,以及擁有強勁的後期研發管線之下,Bausch Health 已具備良好條件來達成這些承諾與目標。考量到許多人可能關心定價問題,我們在今年剩餘期間將不會調漲我們在美國的品牌處方藥價格。Bausch Health 的一項獨特優勢在於,約 54% 的營收來自多元化組合,包括醫療器材、非處方產品、以及在美國以外銷售的處方藥與品牌學名藥。換言之,我們有 54% 的產品不受美國品牌處方藥定價環境影響。

  • In conclusion, let me summarize 3 takeaways. First, I want to thank nearly 21,000 employees of Bausch Health companies whose contributions have delivered another great quarter. Second, we have a durable portfolio of diversified products that represents a unique comfortable strength and the segments representing over 3/4 of our revenues are growing organically in the mid-single digits. Third, our top 10 products in the aggregate are showing double-digit organic growth. Overall, it's been a great first 20 days at Bausch Health.

    總結來說,我想歸納 3 點重點。第一,我要感謝 Bausch Health 旗下公司近 21,000 名員工,他們的貢獻讓我們再度交出亮眼的一季。第二,我們擁有耐久且多元化的產品組合,展現出獨特且令人安心的優勢;而占我們營收超過 3/4 的各事業部,正以中個位數的幅度實現有機成長。第三,我們前 10 大產品合計呈現兩位數的有機成長。整體而言,在 Bausch Health 的前 20 天非常順利。

  • With that operator, let's open up the lines for questions.

    那麼,接線員,讓我們開放電話線進行提問。

  • Operator

    Operator

  • (Operator Instructions) Our first question comes from the line of Gregg Gilbert.

    (接線員指示) 我們的第一個問題來自 Gregg Gilbert 的電話線。

  • Gregory B. Gilbert - MD and Senior Analyst

    Gregory B. Gilbert - MD and Senior Analyst

  • But on the genetic risk front, Joe, other than the state being extended yet again, do you have any insights into Teva's filing? And whether it meets FDA guidance? Or is there anything else you can glean from your interactions with them on that item?

    不過在學名藥風險方面,Joe,除了期限又再度延長之外,你對 Teva 的申請有任何見解嗎?以及它是否符合 FDA 指引?或者你從與他們就此事項的互動中,還能得到其他資訊嗎?

  • And then secondly, on the international -- pharma international piece, can you talk about -- you talked about the volatility, what's driving that? And what are some of the changes you are making there? It sounds like you're still confident in this being a growth business. But can you talk about some of the things that you've been surprised by, if anything? And what you're doing about that?

    第二個問題,關於國際—也就是國際製藥這一塊,你能談談—你提到波動性,是什麼在驅動這些波動?以及你們正在做哪些調整?聽起來你們仍然有信心這會是一門成長型業務。但你能談談是否有任何讓你們意外的地方?以及你們將如何因應?

  • Joseph C. Papa - CEO & Chairman of the Board

    Joseph C. Papa - CEO & Chairman of the Board

  • Sure. So maybe just for -- going back on your first part of your question on the Teva ANDA relative to our XIFAXAN product. Yes, you are correct. We agreed to -- with Teva to extend for another 30 days, the ANDA. That follows a 12-month originally then another 3 months and now 1 month. There really, to our knowledge, have been no changes. Teva appears to have some challenges with their ANDA. I can't speak to exactly their challenges, but it does appear that there are some challenges. I think, from a point of view, of somebody in the -- who's been in the generic market before, if Teva had a viable ANDA pathway, I expect they'd want to move forward quickly as possible. At this point, we continue to extend, but I really can't make any specific comments. So I think you have to check more with Teva on the specifics here.

    好的。那我先回到你第一部分的問題,關於 Teva 針對我們 XIFAXAN 產品所提出的 ANDA。是的,你說得沒錯。我們同意與 Teva 將該 ANDA 再延長 30 天。這是在原本 12 個月、之後再延長 3 個月、現在再延長 1 個月之後的安排。據我們所知,實際上並沒有任何變更。Teva 的 ANDA 似乎遇到一些挑戰。我無法具體說明他們的挑戰是什麼,但看起來確實存在一些困難。以曾在學名藥市場工作過的人來看,如果 Teva 有可行的 ANDA 推進路徑,我預期他們會希望盡快往前推進。目前我們仍在延長,但我無法做出任何具體評論。因此,我想你需要向 Teva 進一步確認相關細節。

  • Paul S. Herendeen - Executive VP & CFO

    Paul S. Herendeen - Executive VP & CFO

  • Yes -- sorry..

    是的—抱歉..

  • Joseph C. Papa - CEO & Chairman of the Board

    Joseph C. Papa - CEO & Chairman of the Board

  • On the second part of the question?

    第二部分的問題呢?

  • Paul S. Herendeen - Executive VP & CFO

    Paul S. Herendeen - Executive VP & CFO

  • Yes, the second part of the question, Gregg, I think you're referring back to the international pharma business, and I called it out in my prepared remarks, it grew 1% and its -- I said that this an area of focus. We are not satisfied with the consistency that we're getting in the performance of some of the geographies. So what this goes back to is, this goes back to management. And it's focus and it's ensuring that we have the right people in place. I think Tom Appio, who runs of our international group is doing a fantastic job. And I think you see the results of that when you looked in that the international part of the Vision Care business, you're looking at international Optho Rx, you're looking at international consumer results, it's all good. But what's lagging a bit is the consistency of performance in international and it boils down to the team that we have in place. And we're -- we've taken steps. Tom continues to take steps, and we're confident that we get that to a place where it'll be a more consistent driver for us. It is certainly -- at this stage, it is lagging behind the great performance that we've seen in some of the other units.

    是的,Gregg,第二部分我想你指的是國際製藥業務。我在事先準備的發言中提到,它成長 1%,而且—我說過這是我們的重點關注領域。我們對於某些地區表現的一致性並不滿意。所以這回到一個問題:管理。也就是專注度,以及確保我們有合適的人在正確的位置上。我認為負責我們國際事業群的 Tom Appio 做得非常出色。你也能從結果看出來:國際視力保健業務、國際眼科處方藥(Optho Rx)、國際消費品的表現都很好。但稍微落後的是國際製藥在表現一致性方面,而這歸根結底取決於我們現有的團隊配置。我們—已採取一些措施。Tom 也持續採取行動,我們有信心能把它改善到更穩定、能更一致地成為我們的成長驅動因素。在現階段,它確實落後於我們在其他事業單位所看到的優異表現。

  • Joseph C. Papa - CEO & Chairman of the Board

    Joseph C. Papa - CEO & Chairman of the Board

  • Gregg, I probably should have also said, relative to our XIFAXAN, obviously, we are very strong about our intellectual property on the product. We believe, we've got a strong intellectual property position with probably more patents and patents that run through well into 2029 time frame.

    Gregg,我可能也應該補充一下,關於我們的 XIFAXAN:顯然,我們對該產品的智慧財產權非常有信心。我們相信我們擁有強而有力的智慧財產權地位,可能有更多專利,而且專利期限可延續到 2029 年左右。

  • Operator

    Operator

  • Our next question comes from the line of Umer Raffat.

    我們的下一個問題來自 Umer Raffat 的電話線。

  • Umer Raffat - Senior MD & Senior Analyst of Equity Research

    Umer Raffat - Senior MD & Senior Analyst of Equity Research

  • First, so Joe or Paul, one of the challenges for many of us who have tracked Valeant and now Bausch over the years has been that reported segments always change nonstop. And I understand the motivation to add visibility on product level, perhaps that could be just done on a product level, not segment level. So my question really is, do you expect there to be additional segment changes over the next, let's say, 2019, 2020? And are you willing to add disclosures for more than just 4 historical quarters? And I had a couple of questions on the business.

    第一,Joe 或 Paul,多年來追蹤 Valeant、以及現在的 Bausch 的我們其中一個困擾是:你們揭露的事業部門分類總是在不停變動。我理解你們想提高產品層級能見度的動機,也許那可以只在產品層級做到,而不必在部門層級調整。所以我的問題是,你們是否預期在接下來例如 2019、2020 年還會有進一步的部門分類變更?以及你們是否願意提供不只 4 個歷史季度的更多揭露?另外我還有幾個關於業務的問題。

  • Joseph C. Papa - CEO & Chairman of the Board

    Joseph C. Papa - CEO & Chairman of the Board

  • Okay. Let me just start with that. We've had a chance to hear a lot from our investors. And one of the things that they've asked us clearly as we've taken over as a new team is to make sure to provide some greater clarity in that business, greater transparency, and we've worked really hard to do that. As you can imagine, the business has changed in the sense that we made some asset divestitures in 2016 and '17. As we looked at how we're running the business in 2018, one of the comments we wanted to do is make sure we had the appropriate segmentations that we could share that with our investors across the board, so we've taken a look at that, and we've done that. And the other thing, of course, is that many people were asking us to have greater visibility in our Salix business versus our dermatology business, and that's one of the other things that this accomplishes, so that is part of what we will do.

    好的。我先從這點開始。我們有機會聽到許多投資人的意見。而且在我們以新團隊接手之後,他們很明確地要求我們,務必在該業務上提供更清楚的說明、更高的透明度;我們也為此非常努力。如你所想像,業務確實有所改變,因為我們在2016年與2017年進行了一些資產剝離。當我們檢視2018年如何營運業務時,我們希望確保有適當的分部劃分,能夠向所有投資人一致地分享,因此我們重新檢視並完成了這件事。另外,當然也有很多人要求我們在Salix業務相對於皮膚科業務方面提供更高的可視性,而這次調整也達成了這一點,所以這也是我們將要做的一部分。

  • Final part of your question is the additional history, we will have that available to you later this week in terms of what will be available, historical commentary will be out -- I think, it'll be by Friday, we'll have it out. Paul anything you want to add on the historical comments on the question?

    你問題的最後一部分是關於補充的歷史資料;我們會在本週稍晚提供給你,就可提供的內容而言,歷史說明將會發布——我想在週五之前我們就會發布。Paul,你對這個問題中關於歷史說明還有什麼要補充的嗎?

  • Paul S. Herendeen - Executive VP & CFO

    Paul S. Herendeen - Executive VP & CFO

  • No. It's Paul speaking, Umer. It's -- I think this segment thing, it starts with wanting to have excellence in execution and putting the right leadership in place, the right structure in place to manage each one of our individual units to drive long-term value. And ultimately, as we've gone through that reorganization process, the accounting and the requirements of our accounting follow that you report your segments the way you manage them. And so I'd say I know it creates some noise for those of you who are trying to follow us and follow us on a segment basis, but we will do our level best to ensure that you have historical information, so you can go back and track how we did come. But this is -- as we're sitting here right now, this is the way we are organized and managed and our accounting follows the way we run the business.

    沒有。Umer,我是Paul。我想這個分部的事情,起點在於希望在執行上做到卓越,並為我們每一個獨立事業單位配置正確的領導、建立正確的架構,以推動長期價值。而最終,當我們走過這個重組流程後,會計處理與會計要求也會跟著走:你必須以你管理業務的方式來報告分部。所以我會說,我知道這會對那些試圖追蹤我們、並以分部角度追蹤我們的人造成一些雜訊,但我們會盡最大努力確保你們能取得歷史資訊,讓你們可以回頭追溯我們是如何走到今天的。但就我們此刻而言,這就是我們的組織與管理方式,而我們的會計也會依照我們經營業務的方式來反映。

  • Umer Raffat - Senior MD & Senior Analyst of Equity Research

    Umer Raffat - Senior MD & Senior Analyst of Equity Research

  • Got it. My question on the business really was, A, do you expect price increases at Valeant to be capped at something like mid-single digits sort of like the commentary we're seeing out of a lot of big pharma? And I guess, how do you expect that to impact your outlook on EBITDA going forward?

    了解。我對業務的問題其實是:A,你們是否預期Valeant的漲價會被限制在例如中個位數百分比左右,就像我們在許多大型藥廠看到的說法那樣?以及,你們預期這會如何影響你們未來對EBITDA的展望?

  • And then secondly, in your slide on XIFAXAN mentioned some color on FDA interactions on a new formulation. So can you just give us more color on what exactly are the indications as well as is it the immediate release or the extended release SSD formulation that you're trying to develop further?

    第二個問題,你們在關於XIFAXAN的投影片中提到,會補充一些與FDA就新劑型互動的資訊。所以你們能否更具體說明:到底是哪些適應症?以及你們要進一步開發的是即釋還是緩釋的SSD劑型?

  • Joseph C. Papa - CEO & Chairman of the Board

    Joseph C. Papa - CEO & Chairman of the Board

  • Okay. So couple comments. On the question on -- as we've noted that we do not expect any additional -- we are not planning or taking any additional price increases in 2018, that is clear. On the question that goes forward discussion, I think, you're asking more about where are we going forward? We've said publicly that we would keep our pricing to single-digit pricing and we put additional comment on single digits and tried to state you with the average for the pharmaceutical over the last 5 years as a commentary on where we would be, which we think is a responsible approach to pricing.

    好的。我有幾點說明。關於價格的問題——如我們先前所提,我們不預期會有任何額外的——我們在2018年不規劃也不會再進行任何額外的漲價,這點很清楚。至於你問到往後的討論,我想你是在問我們未來會怎麼做?我們已公開表示,我們會把定價控制在個位數的漲幅;我們也對「個位數」做了補充說明,並以過去5年製藥產業的平均水準作為我們可能採取的區間參考,我們認為這是負責任的定價方式。

  • On the question -- second part of the question relative to the FDA on XIFAXAN, yes, we have met with the FDA, that is absolutely correct. We are looking at some additional GI indications. I'm not going to go into the specifics of it. But as we post those trials on clinicaltrials.gov, you'll see those additional GI indications. And to be clear, we're looking at both the immediate release and the slow release of the SSD formulations. We've already made that public as we thought about one of the first indications that we're gone going on with XIFAXAN, we posted that on the clinicaltrials.gov for that one indication, that clinical trials already been published. There are some additional indications we're going after with XIFAXAN, they'll be on that one.

    第二部分關於XIFAXAN與FDA的問題,是的,我們已與FDA會面,這完全正確。我們正在評估一些額外的腸胃道(GI)適應症。我不會深入談具體細節。但當我們把那些試驗登錄到clinicaltrials.gov時,你會看到那些額外的GI適應症。另外要說清楚的是,我們同時在評估SSD劑型的即釋與緩釋版本。我們先前已經公開過:在我們思考XIFAXAN要推進的第一個適應症時,我們已把該適應症登錄在clinicaltrials.gov上,而那項臨床試驗也已經公布。我們還有一些XIFAXAN要爭取的額外適應症,也都會在那裡看到。

  • Paul S. Herendeen - Executive VP & CFO

    Paul S. Herendeen - Executive VP & CFO

  • Umar, it's Paul. I want to jump in here as well. Because I think one of the things we faced when we talk about pricing is people look at our business and categorize us as a pharmaceutical company. And as we're sitting here today, like 53% of our revenue is in branded Rx products in the U.S. and the balance is not exposed to that, to the same sorts of pressures that you're seeing out in the marketplace. I think that's an important factoid, and I'm going beg you, please call it Bausch Health.

    Umar,我是Paul。我也想在這裡補充一下。因為我認為當我們談到定價時,我們面臨的一件事是:大家看我們的業務,會把我們歸類為一家製藥公司。但以我們今天的狀況來看,大約53%的營收來自美國的品牌處方藥(branded Rx)產品,其餘部分並不會承受你在市場上看到的那種同樣的壓力。我覺得這是一個重要的事實點,而且我得拜託你,請稱呼我們為Bausch Health。

  • Operator

    Operator

  • Our next question comes from the line of Louise Chen.

    我們的下一個問題來自Louise Chen。

  • Louise Alesandra Chen - Senior Research Analyst & MD

    Louise Alesandra Chen - Senior Research Analyst & MD

  • I had a few. So first question I had was just on your leverage ratio. Do you still see this 4 to 5x over the next several years as realistic? And is that going to be driven by debt pay down and EBITDA expansion or one or the other?

    我有幾個問題。第一個是關於你們的槓桿比率。你們仍然認為未來幾年降到4到5倍是可行且現實的嗎?而這會是由償還債務與EBITDA擴張所驅動,還是其中之一?

  • And then also a question that we get a lot is just on the equity raise to deleverage. Is this still on the table? And what would be a trigger for something like that?

    另外,我們也常被問到透過增資來去槓桿(deleveraging)的問題。這件事還在考慮範圍內嗎?而觸發這類行動的條件會是什麼?

  • And then last question is just on organic growth. What are your targets over the next several years, if you could speak broadly about that? And what are kind of the key drivers to get to you there?

    最後一個問題是關於有機成長。未來幾年你們的目標是什麼?如果可以的話,請從較宏觀的角度談談。以及達成目標的關鍵驅動因素大概有哪些?

  • Paul S. Herendeen - Executive VP & CFO

    Paul S. Herendeen - Executive VP & CFO

  • Louise, it's Paul. I'll try to take most of those. Yes, do we have the prospect of getting to sort of less than 5x levered over the next handful of years? The answer is, yes. I mean, think, you go back, and we provided what we felt was a good outlook for what you could expect for our top line and adjusted EBITDA CAGRs for the next handful of years. And if you have a model, you can come to a point of view about how we can drive our leverage down. How does that happen? It happens the 2 ways that I think you sort of referenced. One is by growing adjusted EBITDA, that's the best way. Second is by prioritizing the use of cash flow we generate from our business to reduce debt. And those are the 2 things that if you just push that over a handful of years, yes, you get a leverage down to, what I'll characterize as, a reasonable and sustainable level.

    Louise,我是Paul。我會盡量回答大部分問題。是的,我們是否有機會在未來幾年把槓桿降到大概低於5倍?答案是:有。我的意思是,你回頭看,我們已提供我們認為合理的展望,說明未來幾年你可以期待我們營收(top line)與調整後EBITDA的年複合成長率(CAGR)大概會是什麼。如果你有一個模型,你就能形成一個觀點:我們如何把槓桿往下拉。那要怎麼做到?我認為主要透過你提到的兩種方式。第一是成長調整後EBITDA,這是最好的方式。第二是把我們業務所產生的現金流優先用來降低負債。而只要把這兩件事在幾年內持續推進,是的,你就會看到槓桿降到我所稱的合理且可持續的水準。

  • Around your question about equity, is that off the table, on the table? We have said consistently for, I guess, the 8-or-so quarters that I've been here, is that when you are levered the way we're levered, it needs to be on the table, it needs to be something we think about. Am I going to disclose on a public call the timing and exactly what we're thinking? No. But it is absolutely something that as a company we think about it to accelerate the process of getting our cap structure to be something more sustainable. And you think about why is that important? It's important for a variety of reasons. One is, we're clearly an outlier with the amount of leverage that we carry, and secondarily, if we can accelerate the process of getting our leverage down, it enables us to loosen up a little bit on the capital allocation for value generative sorts of investments that we would like to make, where today, it's a very limited amount, but we would have the ability to accelerate that. So it's on our minds for sure and for obvious reasons, not going to talk about timing or strategy for equity.

    關於你提到的股權問題,那是完全不考慮、還是在考慮範圍內?我想我們一直都很一致地表示,在我來這裡的大概 8 個季度左右期間,當你像我們這樣使用高槓桿時,這件事就必須列入考量,必須是我們會思考的事情。我會在公開電話會議上揭露時點以及我們確切在想什麼嗎?不會。但這絕對是我們作為一家公司會思考的事情,用以加速讓我們的資本結構變得更可持續的進程。你也會想,為什麼這很重要?重要的原因有很多。第一,我們所承擔的槓桿水準顯然是個異類;第二,如果我們能加速降低槓桿的進程,就能讓我們在資本配置上稍微放鬆一些,去做我們想做、能創造價值的投資;而在今天,這方面的空間非常有限,但我們將有能力加速推進。所以這確實在我們的考量之中,而且原因很明顯,但我不會談股權的時點或策略。

  • Joseph C. Papa - CEO & Chairman of the Board

    Joseph C. Papa - CEO & Chairman of the Board

  • Final comment. I think you, Louise, you had a quick question on the long-term guidance, and I think the only thing I'd to add to what Paul said was that, we've said publicly that we believe our revenue will be in the 4% to 6% range from 2018 to 2021 and the EBITDA will be in the 5% to 8% growth from 2018 and 2021. Those are the facts that we have previously shared on the longer-term, or 3-year CAGRs.

    最後補充一點。Louise,我想你對長期指引有個簡短問題;我唯一想在 Paul 所說之外補充的是,我們已公開表示,我們相信 2018 到 2021 年的營收將落在 4% 到 6% 的區間,而 EBITDA 將在 2018 到 2021 年間達到 5% 到 8% 的成長。這些是我們先前已分享的較長期、或 3 年期 CAGR 的事實。

  • Operator

    Operator

  • Next question comes from the line of David Amsellem from Piper Jaffray.

    下一個問題來自 Piper Jaffray 的 David Amsellem。

  • David A. Amsellem - MD and Senior Research Analyst

    David A. Amsellem - MD and Senior Research Analyst

  • Just a couple. So first on XIFAXAN. So you had some success with the new sales force, but I guess, the question here is, given the promotion in terms of nature of the space, do you need to add more sales and marketing muscle or do more DTC? And I guess, another question is how can you better leverage the sales force with additional products or bringing in additional products? I know you -- that there's the capital structure, but have you given thought to BD, or at least thinking about it creatively?

    我有幾個問題。首先是關於 XIFAXAN。你們的新銷售團隊取得了一些成效,但我想問的是,考量到這個領域推廣的性質,你們是否需要增加更多銷售與行銷火力,或做更多 DTC(直接面向消費者)?另外一個問題是,你們如何透過增加產品、或引進更多產品,來更好地槓桿運用銷售團隊?我知道你們——有資本結構方面的考量,但你們是否有思考 BD(業務開發),或至少以更有創意的方式來思考?

  • And then just on VYZULTA real quick. We're noticing the NRxs look flat based on the chart that you lay it out. So is that just a function of Part D access not kicking in? Or are there competitive headwinds to think about like Rhopressa? Just help us understand what's going on there?

    再快速問一下 VYZULTA。我們注意到,從你們提供的圖表來看,NRx 看起來持平。這只是因為 Part D 的可及性尚未開始發揮作用嗎?或者是否有像 Rhopressa 之類的競爭逆風需要考量?請幫我們理解那邊發生了什麼事?

  • Joseph C. Papa - CEO & Chairman of the Board

    Joseph C. Papa - CEO & Chairman of the Board

  • Sure. So I'll start. In terms of the XIFAXAN and the Salix team, we think they're doing a great job. There we are continuing to look at more sales and marketing activities, but on balance, we think the team has done very well. I mean, if you just look at with the data we shared in terms of moving the primary care growth from 24% share to 44% share in a little more than 2 -- 1.5 years, we think that's outstanding, and we think that's an important part of -- the message is bright, we think, in terms of what we're saying with primary care. The product performs well. It's an episodic treatment for a chronic disorder. So the large part of that fits really well in terms of the message as well as sales and marketing.

    好的。我先回答。就 XIFAXAN 與 Salix 團隊而言,我們認為他們做得非常好。我們仍在持續評估更多銷售與行銷活動,但整體而言,我們認為團隊表現非常出色。如果你看我們分享的數據,在略多於 2——1.5 年的時間內,基層醫療(primary care)的成長占比從 24% 提升到 44%,我們認為這非常亮眼;而且我們認為這是——我們在基層醫療端所傳達訊息中很重要的一部分,我們覺得前景很正面。產品本身表現良好。它是針對慢性疾病的間歇性(episodic)治療。因此,這在訊息傳遞以及銷售與行銷層面都非常契合。

  • The other part of what we're looking at is, is making ourselves more productive. One of the comments I talked about earlier in my comments was cost optimization and revenue enhancement. We're looking at just trying to get more efficient and making sure that the dollars you spend in any of our product areas are going to be associated with the strong return on investment.

    我們在看的另一部分是,如何讓自己更具生產力。我先前提到的一點是成本最佳化與營收提升。我們正在努力提高效率,並確保你在任何產品領域所花的每一塊錢,都能帶來強勁的投資報酬。

  • Final area I want to make sure I touch on was your question on leveraging the business development aspects of the business. We 100% agree with that comment. That's one of the reasons why we added the PLENVU, it was a project that we added where we worked with getting a new formulation in for a colonoscopy preparation product, that product we felt has a superior profile relative to the quantity of volume and also it's a very good tasting product. So we felt it fits very well with what was happening in the marketplace and what the market need was. Beyond that, we've also did the Dr. Falk, 3 additional budesonide products. And we're going to continue to look at, for example, on the RELISTOR team, the pain team, we add the LUCEMYRA for exactly the reasons that you're talking about. We can leverage the time and with the physicians that we have, the relationships we have and bringing additional product that will help make a difference to patient size. So we think all those things work out really well for us.

    最後一個我想確保有回應到的領域,是你關於如何槓桿運用業務開發面的問題。我們百分之百同意這個看法。這也是我們為什麼加入 PLENVU:這是一個我們新增的專案,我們透過合作導入一個新的配方,用於結腸鏡檢查前的腸道清潔準備產品;我們認為該產品在用量體積方面具備更優的特性,而且口感也非常好。因此我們覺得它非常符合市場正在發生的變化以及市場需求。除此之外,我們也與 Dr. Falk 合作,新增了 3 個額外的布地奈德(budesonide)產品。而且我們會持續尋找機會;例如在 RELISTOR 團隊、疼痛團隊方面,我們加入 LUCEMYRA,正是基於你所提到的那些原因。我們可以槓桿運用我們與醫師互動的時間、既有的關係,並引進更多能對病患規模帶來改變的產品。所以我們認為這些對我們都非常有利。

  • I think the last question you had was VYZULTA and the weekly progress. I would say 2 things on that. First and foremost, I remind you that the initial launch quantity we had with VYZULTA was a bottle size that essentially represented 2-month supply. So that's an important note to think about in terms of looking at our numbers. The second thing I would say is though as we continue to see good development in managed care, the market access wins are very strong. We had a number of wins just starting in July, where we currently believe about -- commercially about 70% of the lives are recovered. So we look at and that has been positive for the future with VYZULTA. In addition to that, as I mentioned in the comments during the presentation, we do expect the Part D coverage to expand next year and toward -- end of this year, next year for VYZULTA. And that's a big part of the market because it does drive about 60% of the overall market for glaucoma. We're very pleased with the initial reactions from physicians in terms -- and patients with the success of VYZULTA.

    我想你最後一個問題是關於 VYZULTA 以及每週的進展。我會說有兩點。第一也是最重要的,我要提醒你,VYZULTA 初期上市時的包裝規格是一種瓶裝大小,基本上相當於 2 個月的用量。所以在解讀我們的數字時,這是一個重要的注意事項。第二點是,隨著我們持續在管理式醫療(managed care)端看到良好進展,我們在市場准入方面的勝利非常強勁。我們從 7 月開始拿下了多個准入勝利,目前我們認為——在商業保險端大約有 70% 的涵蓋人群已被恢復(recovered)。因此我們認為這對 VYZULTA 的未來是正面的。此外,正如我在簡報評論中提到的,我們確實預期 Part D 的涵蓋將在今年底到明年進一步擴大,適用於 VYZULTA。而這是市場中很大的一塊,因為它約占整體青光眼市場的 60%。就醫師的初期反應以及——病患對 VYZULTA 成功使用的反饋而言,我們非常滿意。

  • Operator

    Operator

  • Of our next question comes from the line of Chris Schott from JPMorgan.

    下一個問題來自 JPMorgan 的 Chris Schott。

  • Christopher Thomas Schott - Senior Analyst

    Christopher Thomas Schott - Senior Analyst

  • Just 2 here. Maybe first on the price versus volume dynamics for XIFAXAN. I'm still just trying to reconcile the 26% reported growth with the volume trends you are seeing for the business. So I know you highlighted the non-retail channel benefits here. But should we expect this gap of sales growth versus volume growth to continue for the rest of the year? So if you keep growing volume high singles, does that translate to mid-20% sales growth? Or is that trend start to normalize as the year progresses?

    我這裡有兩個問題。首先可能是關於 XIFAXAN 的價格與銷量動態。我仍在嘗試把你們報告的 26% 成長,與你們在業務上看到的銷量趨勢對起來。我知道你們強調了非零售通路在這裡帶來的好處。但我們是否應該預期「銷售額成長」與「銷量成長」之間的這個差距,會在今年剩餘時間持續?也就是說,如果你們的銷量維持高個位數成長,是否就會轉化為 20% 中段的銷售額成長?或者隨著年度推進,這個趨勢會開始正常化?

  • My second question was a longer-term operating margin question and how the P&L is going to evolve. I guess, when I think about your business, you got clearly growth in Bausch, you got XIFAXAN doing really well, you got the new derm launches kind of queued up here, and that seems to be offset by lingering LOEs of very high-margin products. So I guess when I think about the margins, it just seems that you need to make investments in these growth drivers, the stuff that is going away is high margin. Help me understand a little bit of how we get to operating margin expansion for the business given that mix dynamic playing out?

    我的第二個問題是關於較長期的營運利潤率,以及損益表(P&L)將如何演變。我想,當我思考你們的業務時,很明顯 Bausch 在成長,XIFAXAN 表現非常好,新的皮膚科產品上市也已經排隊在這裡,而這些似乎被一些高毛利產品在專利到期(LOE)後的持續影響所抵消。所以我想,當我思考利潤率時,感覺你們需要在這些成長動能上進行投資,而正在流失的部分卻是高毛利。在這樣的組合動態下,請幫我理解一下,我們如何能讓這項業務實現營運利潤率擴張?

  • Joseph C. Papa - CEO & Chairman of the Board

    Joseph C. Papa - CEO & Chairman of the Board

  • Let me start with the XIFAXAN question. I think you picked it up pretty well, Chris, in times of what's happening. We are seeing TRx growth, as, I think, Paul made mention, of accelerating -- and we're seeing it accelerate at 8% as it continues to accelerate, so we think that's obviously very good. Beyond that, there is a non-retail segment that is up even more than 8%. So that, we think, is another addition, it certainly is up more than the retail side. So we think both the retail and the non-retail being up are important part of it. And my recollection is that non-retail is somewhere around 20% of the total XIFAXAN business. So it's an important segment for us.

    我先從 XIFAXAN 的問題開始。我認為你抓得很準,Chris,就目前正在發生的情況而言。我們看到 TRx 成長,如同我想 Paul 提到的,正在加速——而且我們看到它以 8% 的速度加速,並且仍在持續加速,所以我們認為這顯然非常好。除此之外,還有一個非零售的細分市場,成長幅度甚至高於 8%。因此我們認為這是另一個增量,確實比零售端更高。所以我們認為零售與非零售同時成長,都是其中的重要部分。而我記得非零售大約占 XIFAXAN 總業務的 20% 左右。所以這對我們來說是一個重要的細分市場。

  • Beyond that, we did see some improved pricing versus 2017, as Paul made mention of it. And then we've become much more efficient on our gross to net, it's based both on a question of mix and less couponing that we did versus 2017. So if you think back 2017 second quarter was a quarter where we're just finishing some disruption in the team, so we had to give some additional couponing. This year, we've gotten to be much more efficient in the couponing structure we have in the business. So I think those are probably the 3 main areas for it. If you look at our inventory position, they're relatively similar. There is always going to be a little bit of plus or minuses on inventory, but on balance, we think that -- those are really the 3 primary areas for what's happening with XIFAXAN.

    此外,我們確實看到相較於 2017 年有一些定價改善,如同 Paul 提到的。然後我們在 gross-to-net(毛額到淨額)方面變得更有效率,這同時來自組合(mix)因素,以及相較於 2017 年我們減少了優惠券(couponing)。所以如果你回想一下,2017 年第二季是我們剛結束團隊一些動盪的一季,因此我們必須提供一些額外的優惠券。今年,我們在業務中的優惠券結構已經變得更有效率。所以我認為這大概是三個主要面向。如果你看我們的庫存狀況,則相對類似。庫存總是會有一些小幅的正負變動,但整體而言,我們認為——這些確實就是 XIFAXAN 目前情況的三個主要因素。

  • On the question of our longer-term margin structure, I think you diagnosed it well. All I would say though is think about the fact that we now have latest quarter in terms of where we are, Bausch Health business in total. Bausch + Lomb is 57% of the business, up 4%, Salix up 21 -- 21% of the business, up 14%. Together 78% of the business is growing 6% organically, an important part of it. Take that and, once we get the derm business turned around, which we're making good progress on, then I think that's where we'll be able to see the improvements in the -- in being able to offset LOEs. And most of the LOEs, we -- the major brunt of them we've already worked our way through. As Paul made mention, there are some additional ones happening second half of the year, but most of them we're working our way through. But Paul, anything you wanted to add to the question on the margin?

    關於我們較長期的利潤率結構問題,我認為你的診斷很到位。不過我想說的是,請想想我們現在最新一季的狀況,就整體 Bausch Health 業務而言。Bausch + Lomb 占業務的 57%,成長 4%;Salix 占 21%——占業務的 21%,成長 14%。兩者合計占業務的 78%,有機成長 6%,這是其中很重要的一部分。把這點納入考量,並且一旦我們把皮膚科業務扭轉過來——我們在這方面正取得良好進展——那我認為我們就能看到改善,並能夠抵消專利到期(LOE)的影響。而且大多數的 LOE——我們已經把主要衝擊走過了。如同 Paul 提到的,下半年還會有一些額外的情況發生,但大多數我們都正在逐步走過。不過 Paul,你對於利潤率這個問題還有什麼想補充的嗎?

  • Paul S. Herendeen - Executive VP & CFO

    Paul S. Herendeen - Executive VP & CFO

  • Yes, I mean, it's one of -- as everyone here knows, it's one of favorite topics is you're always looking for ways so we can improve our operating margins. You look at what is now our 4 segments, and each of the 4 segments has its own individual dynamic. I mean, the B + L segment is kind of a 30%-ish operating margin business, but it has -- the advantage to it is that it has great durability, duration associated with that overall segment. How do you get better there, it's through continuous focus on operating expense efficiency in that business, and obviously, if we can continue to grow the top line on a base, we should be able to get some operating leverage in B + L. Salix is kind of a 60% operating margin and a business that if we continue to grow the top line, we should be able to get some operating leverage there as well because we're easily well configured to support the portfolio of brands that we market within Salix. The Ortho Dermatologic segment, as Joe just called out, that's a business that has been undergoing some challenges and contracting. As we introduce the new innovative products into that portfolio, we'd expect to be able to improve the operating margins in that business. And the Diversified is absolutely were the bulk of very high-value LOE assets or high-margin LOE assets resides. And frustrating thing for the team here, those LOE assets and the reason why we call them out for you and show them to you as visibly as possible is there is just nothing we can do about what's going to happen there. So we focus on the balance of the business that we think of as our base business, and we believe that we can drive improvements in operating expenses. If you include the LOE assets in there, yes, you got to wait till we put many of those in the rearview mirror, and once we do that, we would expect to expand of our operating margin from that point. Good question Chris.

    是的,我的意思是——如同在座各位都知道的,這是我最喜歡的主題之一:你總是在尋找我們可以改善營運利潤率的方法。你看看我們現在的 4 個事業部門,每一個部門都有其各自的動態。也就是說,B + L 部門大概是 30% 左右的營運利潤率業務,但它的優勢在於,整個部門具有很強的耐久性與持續性。要如何在那裡做得更好?就是持續聚焦於該業務的營運費用效率;而且很明顯地,如果我們能在既有基礎上持續成長營收(top line),我們應該能在 B + L 取得一些營運槓桿。Salix 大概是 60% 的營運利潤率;如果我們持續成長營收,我們也應該能在那裡取得一些營運槓桿,因為我們的配置很容易支援 Salix 內我們所行銷的品牌組合。Ortho Dermatologic 部門,如 Joe 剛剛指出的,那是一個一直面臨一些挑戰並且在萎縮的業務。隨著我們把新的創新產品導入該產品組合,我們預期能改善該業務的營運利潤率。而 Diversified 部門則是絕大多數高價值 LOE 資產或高毛利 LOE 資產所在之處。對這裡的團隊來說令人沮喪的是,這些 LOE 資產——我們之所以特別向你們點出並盡可能清楚地呈現——是因為那裡將發生的事情我們真的無能為力。因此我們把重點放在我們視為基礎業務(base business)的其餘部分,我們相信可以推動營運費用的改善。如果把 LOE 資產也算進去,是的,你必須等到我們把其中許多放到後照鏡裡(成為過去),一旦做到,我們預期從那個時間點起,我們的營運利潤率將會擴張。問得很好,Chris。

  • Joseph C. Papa - CEO & Chairman of the Board

    Joseph C. Papa - CEO & Chairman of the Board

  • The only other thing that I would add in thinking about your question a little bit more is that I want you to be -- your hypothesis is correct, but just to be clear, the team in the neuro Diversified business is not sitting still. They -- we're doing something that -- we mentioned shopping in our own closet. We're basically going out and promoting some of the products that are in that business. And I'd just point to maybe 2 examples that if you look in our appendix, you can look at the Wellbutrin and the Aplenzin promotion and response curve. You can see that those 2 products together in the quarter are growing significantly. If you look at the Page 35 in our business, the growth in Wellbutrin franchise and the Aplenzin franchise, you see some very nice growth versus the year-ago quarter. And that's really result of some of the things we're doing to help to grow some of these Diversified products. Even though we -- you're absolutely correct, we do face some LOEs, and Paul's comments stands correct as stated. But we are out looking for these opportunities where we think our products can help patients, and if we can, we think that we'll get some growth.

    另外我想補充的一點是,進一步思考你的問題時,我希望你——你的假設是正確的,但要說清楚的是,神經(neuro)Diversified 業務的團隊並沒有停滯不前。他們——我們正在做一件事——我們提到過「在自家衣櫥裡購物」。基本上我們正走出去推廣該業務中的一些產品。我想指出兩個例子:如果你看我們的附錄,你可以看到 Wellbutrin 與 Aplenzin 的推廣與反應曲線。你可以看到這兩個產品合計在本季成長顯著。如果你看我們業務簡報的第 35 頁,Wellbutrin 產品線與 Aplenzin 產品線的成長,你會看到相較於去年同期有相當不錯的成長。而那確實是我們正在做的一些事情所帶來的結果,用以協助推動這些 Diversified 產品的成長。即使我們——你完全正確,我們確實面臨一些 LOE,而 Paul 的評論也如其所述仍然正確。但我們正在外部尋找這些機會,在我們認為產品能幫助病患的地方,如果可以,我們認為就能帶來一些成長。

  • Operator

    Operator

  • Our next question comes from the line of David Risinger.

    我們的下一個問題來自 David Risinger 的提問。

  • David Reed Risinger - MD in Equity Research and United States Pharmaceuticals Analyst

    David Reed Risinger - MD in Equity Research and United States Pharmaceuticals Analyst

  • So I have 2 questions. First, Bausch Global Consumer was flattish this quarter. If you could just talk about the prospects for Bausch Consumer?

    我有兩個問題。第一,Bausch Global Consumer 本季大致持平。你們能否談談 Bausch Consumer 的前景?

  • And then second, with respect to forthcoming PDUFAs and launches, could you just discuss your expectations how we should think about those opportunities? And then also incremental SG&A spending requirements associated with those launches relative to your current spend base?

    第二,關於即將到來的 PDUFA 與上市(launch),你們能否談談你們的預期,以及我們應該如何看待這些機會?另外,與這些上市相關、相對於你們目前支出基礎的增量 SG&A(銷售、一般及行政費用)支出需求是如何?

  • Paul S. Herendeen - Executive VP & CFO

    Paul S. Herendeen - Executive VP & CFO

  • David, just in terms of the Global Consumer, impacted by divestitures. I mean, if you look at the organic change in our Global Consumer business it was plus 5%. And as I called it out, it's really helped along by really good performance in the U.S. But globally, plus 5% on an organic basis. So that business is going well and not just well in the U.S.

    David,就全球消費者業務而言,受到資產剝離的影響。我的意思是,如果你看我們全球消費者業務的有機變動,是成長5%。而且如我所指出的,這很大程度上受惠於美國市場非常好的表現。但就全球而言,以有機基礎計算是成長5%。所以這項業務表現良好,而且不只是美國表現好。

  • Joseph C. Papa - CEO & Chairman of the Board

    Joseph C. Papa - CEO & Chairman of the Board

  • The second part of your question was on PDUFA and some of the launches we have and where we were going to be spending money. I think you're referring to not just within the Bausch + Lomb segment, but across the business, is that correct David?

    你問題的第二部分是關於PDUFA,以及我們的一些產品上市計畫,以及我們將把資金花在哪些地方。我想你指的不僅是在Bausch + Lomb部門內,而是涵蓋整個業務,對嗎David?

  • David Reed Risinger - MD in Equity Research and United States Pharmaceuticals Analyst

    David Reed Risinger - MD in Equity Research and United States Pharmaceuticals Analyst

  • Yes, correct.

    是的,沒錯。

  • Joseph C. Papa - CEO & Chairman of the Board

    Joseph C. Papa - CEO & Chairman of the Board

  • Okay. So I mean, I think as we said, across the portfolio, if you look at the launches we have, we feel that each business has some growth, and we're going to continue to invest on the research and development side. We're increasing our investment in research and development this year to make sure we get these products across the finish line. I will say that the Complete Response Letter on DUOBRII was a disappointment, but the team has already addressed what we think the issues are, met with the FDA. Our belief is we'll get that filed within the next 30 days, if not sooner.

    好的。所以我的意思是,我想如我們所說,放眼整個產品組合,如果你看我們即將推出的產品,我們認為每個業務都有一些成長空間,而我們將持續在研發端投入。我們今年會增加研發投資,以確保這些產品能順利完成最後階段。我會說,DUOBRII收到完整回覆函(CRL)令人失望,但團隊已經針對我們認為的問題完成處理,並與FDA會面。我們相信會在未來30天內完成申報,甚至可能更快。

  • On the question of the other products that we clearly think there's some additional dermatology products that will be forthcoming, we think that is the solution to turning around the dermatology business, launch some products, get them out to be successful. We don't foresee significant increases in operating expense. We believe we've already made the investment starting in the first quarter of 2018 in the incremental sales force and responsibilities for the launches of our dermatology business. In our GI category, we're well positioned with PLENVU. To add PLENVU to our current capable sales force as well as the LUCEMYRA product, we're going to add that to the pain team with our RELISTOR opioid. So we think there is a good synergy in adding additional products to the bag of the current sales force and their capabilities.

    至於其他產品的問題,我們明確認為接下來還會有一些額外的皮膚科產品推出;我們認為這是扭轉皮膚科業務的解方:推出產品、把產品推向市場並取得成功。我們不預期營運費用會大幅增加。我們相信自2018年第一季起,已就皮膚科業務的產品上市,在增量銷售人力與職責方面完成投資。在我們的腸胃(GI)領域,我們在PLENVU方面具備良好布局。把PLENVU加入我們目前有能力的銷售團隊,以及LUCEMYRA產品,我們會把它加入疼痛團隊,與我們的RELISTOR鴉片類藥物產品一起推廣。因此,我們認為把更多產品加入現有銷售團隊的產品組合與能力中,能帶來良好的協同效益。

  • And then finally, the area in Bausch + Lomb, we have the new contact lens, silicone hydrogel daily launch will start in the fourth quarter. We think that's going to fit in very well with what we said. The only thing that Paul made mention out there, just I'll say briefly, we do see some growth capital requirements for that. That will be something that we're configured for this short-term fine, but as we have some good success with that, there would be some opportunities to expand in our growth capital for that. But overall, we think our overall expenditures are good. We're going to seek to make them more productive relative to using return on investment analysis.

    最後,在Bausch + Lomb方面,我們的新隱形眼鏡——矽水膠日拋——將在第四季開始上市。我們認為這會非常符合我們先前所說的方向。Paul唯一提到的一點,我簡要說明:我們確實看到這方面有一些成長資本需求。短期內我們的配置沒有問題,但若取得良好成功,將有機會擴大相關的成長資本投入。但整體而言,我們認為總體支出水準是合適的。我們將透過投資報酬(ROI)分析,努力讓支出更具生產力。

  • Paul S. Herendeen - Executive VP & CFO

    Paul S. Herendeen - Executive VP & CFO

  • I'm going to come back because I had -- it took me a second to find it in my binder, but I can't (inaudible) factoid slip by. I think the Global Consumer business, again, up 5% and that was comprised of up 8% organically in the U.S. and up 4% outside the U.S. As I said, it's better in the U.S.

    我想補充一下,因為我——我花了一點時間才在資料夾裡找到,但我不能讓那個(聽不清)數據就這樣略過。我認為全球消費者業務同樣是成長5%,其中美國以有機基礎成長8%,美國以外地區以有機基礎成長4%。如我所說,美國表現更好。

  • Joseph C. Papa - CEO & Chairman of the Board

    Joseph C. Papa - CEO & Chairman of the Board

  • Operator, last question. Time for last question, please.

    接線員,最後一個問題。請進行最後一個問題。

  • Operator

    Operator

  • Next question comes from the line of Douglas Tsao.

    下一個問題來自Douglas Tsao。

  • Douglas Dylan Tsao - Director & Senior Research Analyst

    Douglas Dylan Tsao - Director & Senior Research Analyst

  • Just 2 quick ones. First, if you can provide a little color on the performance of the Ultra line from Bausch, that looked up nicely on a sequential basis and the key drivers of growth there?

    兩個簡短問題。第一,能否多提供一些關於Bausch的Ultra產品線表現的說明?看起來按季比較有不錯的成長,主要的成長驅動因素是什麼?

  • And then in terms of the CRL on DUOBRII, it sounds like you have a good hand on what the agency is looking for. Just curious, if you have any perspectives on whether that could affect the filings for BRYHALI and some other products that are in the pipeline, and is this reflects sort of a change in what the FDA is looking for in terms of some topical therapies? Especially sort of fixed-dose combinations. And whether you might need to sort of adjust the filings or make amendments there as well?

    第二,關於DUOBRII的CRL,聽起來你們已經很清楚主管機關在尋求什麼。我想了解的是,你們是否認為這可能會影響BRYHALI以及其他一些管線產品的申報?以及這是否反映FDA對某些外用療法的要求有所改變?特別是固定劑量複方。以及你們是否也需要相應調整申報內容或進行修訂?

  • Joseph C. Papa - CEO & Chairman of the Board

    Joseph C. Papa - CEO & Chairman of the Board

  • Okay. So on the -- I guess, let me start with the Ultra one first. We think that obviously the success with Ultra has been predominantly the launch of the new toric and multi-focal, those we're seeing some very significant organic growth in, especially the toric that we did not have before and that's driving a large percentage of the growth. The important comment here is we've been able to make the investment in the Ultra portfolio, put additional capacity available in the last couple of years, that has given us a chance to launch the full range of the Ultra portfolio, including the toric and multifocal. Once you have that full range, the physicians are -- or the doctors are much more likely to use that product for their patients. So that was an important step that we had to make and that certainly was in the U.S. And then in the rest of the world, our business is growing pretty much across the board in places that where we have the strongest position. Places like China and Thailand and India, we have some pretty strong growth predominantly because we are going in market that are growing relatively quickly would be my comments there.

    好的。那麼關於——我想我先從Ultra這題開始。我們認為,Ultra的成功主要來自新款散光(toric)與多焦(multi-focal)產品的上市;我們在這些產品上看到非常顯著的有機成長,尤其是散光款,這是我們以前沒有的,並帶動了很大比例的成長。這裡重要的一點是:過去幾年我們已在Ultra產品組合上完成投資,並增加了可用產能,讓我們有機會推出Ultra的完整產品線,包括散光與多焦。一旦具備完整產品線,醫師——或醫生——就更可能把該產品用於他們的病患。因此,那是我們必須完成的一個重要步驟,而這當然主要發生在美國。至於世界其他地區,我們的業務在我們最具優勢的市場幾乎全面成長。像中國、泰國、印度等地,我們有相當強勁的成長,主要是因為我們進入的市場本身成長相對快速——以上是我的看法。

  • I think the second part of the question was BRYHALI, we do not believe that the complete response letter, specific information request will have an impact on BRYHALI. But having said that, we now understand what the FDA's requirements are. And as a result of that, we'll continue to work very closely with not just DUOBRII and BRYHALI, but in all of our applications to make sure that we answer the FDA's questions and make sure that they're put into the initial filings as we go forward. But bottom line is we do not feel at this time that BRYHALI would be impacted by the same questions that DUOBRII had from the FDA pharmacokinetic point of view. So I think clearly, we'll continue to learn and get better in terms of the filings that we put forward in the marketplace.

    我想問題的第二部分是關於BRYHALI;我們不認為這封完整回覆函(CRL)中針對特定資訊的要求會對BRYHALI造成影響。但話雖如此,我們現在已了解FDA的要求是什麼。因此,我們將持續與DUOBRII與BRYHALI不僅如此,也與所有申請案密切合作,確保我們回覆FDA的問題,並在後續推進時把這些內容納入初始申報資料中。但總結來說,目前我們不覺得BRYHALI會受到與DUOBRII相同的問題影響,尤其是從FDA藥物動力學(pharmacokinetic)的角度來看。所以我認為很明顯地,我們會持續學習,並在我們向市場提交的申報文件品質上持續精進。

  • Operator, that concludes our call today. I'd like to thank everyone for participating in the call. Thank you, and have a great day, everyone.

    接線員,今天的電話會議到此結束。我要感謝各位參與本次電話會議。謝謝大家,祝各位今天愉快。

  • Operator

    Operator

  • This concludes today's conference call. You may now disconnect.

    本日電話會議到此結束。您現在可以掛線。